blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3943488

EP3943488 - SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  24.12.2021
Database last updated on 28.09.2024
FormerThe international publication has been made
Status updated on  03.10.2020
Most recent event   Tooltip08.05.2024New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
Genfleet Therapeutics (Shanghai) Inc.
Level 2/3/4/5, Suite 8
1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
For all designated states
Zhejiang Genfleet Therapeutics Co., Ltd.
4th Floor, No.3 South Building
Medical Technology Industrial Park
No.1 Yunhai Road
Lihai Town
Shaoxing Binhai New City, Zhejiang 312000 / CN
[N/P]
Former [2022/04]For all designated states
Genfleet Therapeutics (Shanghai) Inc.
Level 2/3/4/5, Suite 8
1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
For all designated states
Zhejiang Genfleet Therapeutics Co., Ltd.
4th Floor
No.3 South Building, Medical Technology Industrial
Park, No.1 Yunhai Road, Lihai Town
Shaoxing Binhai New City, Zhejiang 312000 / CN
Inventor(s)01 / ZHOU, Fusheng
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
02 / XU, Xiaoming
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
03 / ZHANG, Leitao
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
04 / LIU, Zhubo
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
05 / HU, Gang
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
06 / DING, Qian
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
07 / XIE, Fubo
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
08 / ZHENG, Biao
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
09 / LV, Qiang
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
10 / LAN, Jiong
Level 2/3/4/5 Suite 8, 1206 Zhangjiang Road
Pudong District
Shanghai 201203 / CN
[N/P]
Former [2022/04]01 / ZHOU, Fusheng
Shanghai 201203 / CN
02 / XU, Xiaoming
Shanghai 201203 / CN
03 / ZHANG, Leitao
Shanghai 201203 / CN
04 / LIU, Zhubo
Shanghai 201203 / CN
05 / HU, Gang
Shanghai 201203 / CN
06 / DING, Qian
Shanghai 201203 / CN
07 / XIE, Fubo
Shanghai 201203 / CN
08 / ZHENG, Biao
Shanghai 201203 / CN
09 / LV, Qiang
Shanghai 201203 / CN
10 / LAN, Jiong
Shanghai 201203 / CN
Representative(s)Abel & Imray LLP
Westpoint Building
James Street West
Bath BA1 2DA / GB
[2022/04]
Application number, filing date20777468.820.03.2020
[2022/04]
WO2020CN80306
Priority number, dateCN20191022179922.03.2019         Original published format: CN201910221799
[2022/04]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020192562
Date:01.10.2020
Language:ZH
[2020/40]
Type: A1 Application with search report 
No.:EP3943488
Date:26.01.2022
Language:EN
[2022/04]
Search report(s)International search report - published on:CN01.10.2020
(Supplementary) European search report - dispatched on:EP09.08.2022
ClassificationIPC:C07D277/82, C07D471/04, A61K31/428, A61K31/437, A61P31/00
[2022/04]
CPC:
C07D417/04 (EP,US); C07D471/04 (EP,KR,US); A61K31/437 (EP,KR);
A61K31/4375 (EP); A61K31/4439 (EP); A61K31/444 (EP,KR);
A61K31/4545 (EP,KR); A61K31/496 (EP); A61P1/00 (KR);
A61P17/06 (KR); A61P19/02 (KR); A61P29/00 (KR);
A61P31/00 (EP); A61P9/04 (KR); C07D417/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/04]
TitleGerman:SUBSTITUIERTE HETEROCYCLISCHE AMIDVERBINDUNG UND HERSTELLUNGSVERFAHREN DAFÜR UND PHARMAZEUTISCHE VERWENDUNG DAVON[2022/04]
English:SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF[2022/04]
French:COMPOSÉ AMIDE HÉTÉROCYCLIQUE SUBSTITUÉ AINSI QUE SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE[2022/04]
Entry into regional phase13.10.2021Translation filed 
13.10.2021National basic fee paid 
13.10.2021Search fee paid 
13.10.2021Designation fee(s) paid 
13.10.2021Examination fee paid 
Examination procedure13.10.2021Examination requested  [2022/04]
27.01.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
07.02.2022Renewal fee patent year 03
21.03.2023Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
31.03.202405   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[A]WO2006038116  (WARNER LAMBERT CO [US], et al) [A] 2, 3, 6, 8-16, 18-21* entire document *;
 [A]WO2009017822  (AMGEN INC [US], et al) [A] 1, 3-7, 11-17, 19-21 * entire document *;
 [X]WO2018148626  (BRISTOL MYERS SQUIBB CO [US]) [X] 2, 3, 6, 8-16, 18-21 * claim 1, description, page 24, line 20 to page 26, line 17, and page 27, lines 26 and 27, and page 67, lines 1-4 *;
 [A]CN109053630  (UNIV PLA 2ND MILITARY MEDICAL) [A] 1, 3-7, 11-17, 19-21 * claims 1 and 5-10, and description, paragraphs [0094]-[0097] *
by applicant   - Cell, (19950000), vol. 81, pages 513 - 523
    - Immunity, (19970000), vol. 7, pages 821 - 830
    - Immunity, (19960000), vol. 4, pages 387 - 396
    - Nat Immunol, (20040000), vol. 5, pages 503 - 507
    - EMBO Rep, (20090000), vol. 10, pages 916 - 922
    - J.Biol.Chem., (19990000), vol. 274, pages 16871 - 16875
    - Curr.Biol., (19990000), vol. 9, pages 539 - 542
    - J.Biol.Chem., (20050000), vol. 280, pages 36560 - 36566
    - Cell Signal, (20150200), vol. 27, no. 2, pages 306 - 14
    - J.Biol.Chem., (20040000), vol. 279, pages 7925 - 7933
    - Cell, (20030000), vol. 114, pages 181 - 190
    - Mol.Cell, (20060000), vol. 22, pages 245 - 257
    - J.Mol.Biol., (20100000), vol. 396, pages 528 - 539
    - Nat.Immunol, (20080000), vol. 9, pages 1037 - 1046
    - Proc.Natl.Acad.Sci.USA., (20080000), vol. 105, pages 11778 - 11783
    - Sci.Signal, (20100000), vol. 115, page re4
    - Cell Death Dis, (20110000), vol. 2, page 2e115
    - FEBS J, (20120000), vol. 278, pages 877 - 887
    - Cell, (20120000), vol. 148, pages 228 - 243
    - Proc.Natl.Acad.Sci.USA., (20120000), vol. 109, pages 5322 - 5327
    - Nat.Rev.Immunol, (20080000), vol. 8, pages 279 - 289
    - Nature, (20110000), vol. 477, pages 330 - 334
    - Immunity, (20110000), vol. 35, pages 908 - 918
    - PNAS, (20100000), vol. 107, pages 21695 - 21700
    - Proc.Natl.Acad.Sci., (20120000), vol. 109, no. 36, pages 14598 - 14603
    - Cell, (20090000), vol. 137, pages 1100 - 1111
    - Nat.Chem.Biol., (20050000), vol. 1, pages 112 - 119
    - J.Neurosci.Res., (20100000), vol. 88, pages 1569 - 1576
    - Kidney Int, (20120000), vol. 81, pages 751 - 761
    - Ren.Fail., (20120000), vol. 34, pages 373 - 377
    - Neurochem.Res., (20120000), vol. 37, pages 1849 - 1858
    - Genes Dev, (20130000), vol. 27, pages 1640 - 1649
    - Cell Host&Microbe, (20140000), vol. 15, pages 23 - 35
    - Cell, (20130000), vol. 153, pages 1 - 14
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.